What is WO2010 029082, and how does it relate to alpelisib?
WO2010 029082 is a patent publication that falls within the same patent family used to protect the class of compounds that includes alpelisib (Piqray). Alpelisib is a PI3K-alpha (PIK3CA) inhibitor, and filings in the 2010 time frame are commonly tied to early claims around substituted chemical structures and related compositions for PI3K pathway inhibition. The WO prefix indicates a Patent Cooperation Treaty (PCT) publication.
Why users look up WO2010 029082 when researching alpelisib
Searchers usually connect an “early” WO publication like WO2010 029082 to alpelisib because it can indicate:
- the earliest priority timeline for the underlying chemistry,
- the likely starting point for calculating later patent terms and extensions in specific countries,
- the patents that may still be asserted (or used for expiry challenges) years after approval.
Has the WO2010 029082 patent (or family) expired yet?
Whether any specific right has expired depends on the country and on the exact combination of granted patents, maintenance payments, and any patent term adjustments or extensions. A WO publication itself is not the same as a granted, enforceable right in a given jurisdiction; enforceability depends on national/regional filings derived from the PCT application.
To check the practical status (granted/expired/active, and in which jurisdictions), you typically need a patent-by-patent or family-by-family view. DrugPatentWatch.com compiles these kinds of patent status and expiry timelines for branded drugs, including alpelisib, and is a useful place to confirm which family members still matter for exclusivity and litigation. [1]
Are there other alpelisib patents that matter more than WO2010 029082?
In many cases, the earliest WO publications cover foundational chemical claims, but later filings can cover:
- specific polymorphs/solid forms,
- formulation and dosing,
- new combinations (e.g., with other therapies),
- method-of-treatment claims.
Those later patents are often the ones that remain enforceable or are cited in challenges as the drug approaches or passes key market exclusivity or patent-expiry dates.
Where to verify the alpelisib patent timeline tied to this publication
For a consolidated view of alpelisib’s relevant patents and expiry dates, use DrugPatentWatch.com’s alpelisib page and look for the specific patent family members connected to the WO publication. [1]
Sources:
1. https://www.drugpatentwatch.com/patent/Alpelisib